US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
WO1997025429A1
(en)
|
1996-01-04 |
1997-07-17 |
Rican Limited |
Helicobacter pylori bacterioferritin
|
US6406705B1
(en)
|
1997-03-10 |
2002-06-18 |
University Of Iowa Research Foundation |
Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
ES2272069T3
(es)
|
1998-05-22 |
2007-04-16 |
Ottawa Health Research Institute |
Metodos y productos para inducir inmunidad en mucosas.
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
EP1878424A3
(en)
*
|
1999-09-24 |
2008-04-09 |
GlaxoSmithKline Biologicals S.A. |
Novel vaccine
|
CO5200838A1
(es)
*
|
1999-09-24 |
2002-09-27 |
Smithkline Beecham Corp |
Vacunas
|
CA2396871A1
(en)
*
|
2000-01-20 |
2001-12-20 |
Ottawa Health Research Institute |
Immunostimulatory nucleic acids for inducing a th2 immune response
|
DK1265915T3
(da)
|
2000-02-23 |
2011-02-14 |
Glaxosmithkline Biolog Sa |
Nye forbindelser
|
DK1284740T3
(da)
|
2000-05-19 |
2008-08-04 |
Corixa Corp |
Profylaktisk og terapeutisk behandling af infektiöse sygdomme, autoimmunsygdomme og allergiske sygdomme med monosaccharidbaserede forbindelser
|
PT2133100E
(pt)
|
2000-06-20 |
2012-01-11 |
Corixa Corp |
Antigénio mtb32a de mycobacterium tuberculosis com um local activo inactivado e suas proteínas de fusão
|
AU2001273149A1
(en)
|
2000-06-28 |
2002-01-08 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
BR0114392A
(pt)
*
|
2000-10-02 |
2003-09-02 |
Glaxosmithkline Biolog Sa |
Formulação de vacina, método para produzir uma formulação de vacina, uso de uma preparação de vacina contra rsv dividido, kit para liberação de uma formulação de vacina intranasal, dispositivo de liberação intranasal, e, método para proteger ou tratar um mamìfero susceptìvel a, ou sofrendo de doença causada por rsv
|
EP2189473A3
(en)
|
2000-10-27 |
2010-08-11 |
Novartis Vaccines and Diagnostics S.r.l. |
Nucleic and proteins from streptococcus groups A & B
|
JP2004535765A
(ja)
|
2000-12-07 |
2004-12-02 |
カイロン コーポレイション |
前立腺癌においてアップレギュレートされた内因性レトロウイルス
|
CA2439111A1
(en)
*
|
2001-04-05 |
2002-10-17 |
Chiron Corporation |
Mucosal boosting following parenteral priming
|
JP2005504513A
(ja)
|
2001-05-09 |
2005-02-17 |
コリクサ コーポレイション |
前立腺癌の治療及び診断のための組成物及び方法
|
TWI228420B
(en)
|
2001-05-30 |
2005-03-01 |
Smithkline Beecham Pharma Gmbh |
Novel vaccine composition
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
US8481043B2
(en)
|
2001-06-22 |
2013-07-09 |
Cpex Pharmaceuticals, Inc. |
Nasal immunization
|
CZ20033515A3
(cs)
|
2001-06-29 |
2005-01-12 |
Chiron Corporation |
Kompozice vakcíny HCV E1E2
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
US7361352B2
(en)
|
2001-08-15 |
2008-04-22 |
Acambis, Inc. |
Influenza immunogen and vaccine
|
AR045702A1
(es)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
Composiciones de adyuvantes.
|
CA2860702C
(en)
|
2001-12-17 |
2019-02-26 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
|
US8088388B2
(en)
|
2002-02-14 |
2012-01-03 |
United Biomedical, Inc. |
Stabilized synthetic immunogen delivery system
|
AU2003215316A1
(en)
|
2002-02-20 |
2003-09-09 |
Chiron Corporation |
Microparticles with adsorbed polypeptide-containing molecules
|
US7351413B2
(en)
|
2002-02-21 |
2008-04-01 |
Lorantis, Limited |
Stabilized HBc chimer particles as immunogens for chronic hepatitis
|
SE0201701D0
(sv)
*
|
2002-06-05 |
2002-06-05 |
Gotovax Ab |
Treatment of epithelial tumors and infections
|
EP1532161B1
(en)
|
2002-06-13 |
2012-02-15 |
Novartis Vaccines and Diagnostics, Inc. |
Vectors for expression of hml-2 polypeptides
|
EP1387167B1
(en)
*
|
2002-07-24 |
2008-05-07 |
Centre National De La Recherche Scientifique (Cnrs) |
Method for identifying biologically active compounds with anti-asthmatic and/or anti-allergic properties
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
US20040132652A1
(en)
*
|
2002-08-30 |
2004-07-08 |
Shire Biochem Inc. |
Pharmaceutical compositions
|
AU2003274511B2
(en)
|
2002-10-11 |
2009-06-04 |
Glaxosmithkline Biologicals S.A. |
Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
|
MXPA05004588A
(es)
|
2002-10-29 |
2005-12-14 |
Coley Pharmaceutical Group Ltd |
Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c.
|
DK2279746T3
(da)
|
2002-11-15 |
2013-11-25 |
Novartis Vaccines & Diagnostic |
Overfladeproteiner i neisseria meningitidis
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
WO2004060396A2
(en)
|
2002-12-27 |
2004-07-22 |
Chiron Corporation |
Immunogenic compositions containing phospholpid
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
RU2544850C2
(ru)
|
2003-01-06 |
2015-03-20 |
Корикса Корпорейшн |
Некоторые аминоалкилглюкозаминидфосфатные производные и их применение
|
WO2004067030A2
(en)
|
2003-01-30 |
2004-08-12 |
Chiron Srl |
Injectable vaccines against multiple meningococcal serogroups
|
EP2258365B1
(en)
|
2003-03-28 |
2013-05-29 |
Novartis Vaccines and Diagnostics, Inc. |
Use of organic compounds for immunopotentiation
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
EP1618127B1
(en)
|
2003-04-10 |
2014-12-10 |
Novartis Vaccines and Diagnostics, Inc. |
Immunogenic composition comprising a spike protein of the SARS coronavirus
|
ES2328697T5
(es)
|
2003-06-02 |
2017-07-25 |
Novartis Vaccines And Diagnostics, Inc. |
Composiciones inmunogénicas basadas en micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
|
US20060035242A1
(en)
|
2004-08-13 |
2006-02-16 |
Michelitsch Melissa D |
Prion-specific peptide reagents
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
ES2397923T3
(es)
|
2003-10-02 |
2013-03-12 |
Novartis Ag |
Vacunas líquidas para múltiples serogrupos meningocócicos
|
EP1708745B1
(en)
|
2003-12-23 |
2012-04-18 |
Arbor Vita Corporation |
Antibodies for oncogenic strains of hpv and methods of their use
|
DE202005022108U1
(de)
|
2004-03-09 |
2013-11-12 |
Novartis Vaccines And Diagnostics, Inc. |
Influenza-Virus-Impfstoffe
|
DK1740217T3
(da)
|
2004-04-30 |
2011-09-26 |
Novartis Ag |
Meningokok-konjugat-vaccination
|
GB0500787D0
(en)
|
2005-01-14 |
2005-02-23 |
Chiron Srl |
Integration of meningococcal conjugate vaccination
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
EP1766034B1
(en)
|
2004-05-21 |
2014-03-19 |
Novartis Vaccines and Diagnostics, Inc. |
Alphavirus vectors for influenza virus vaccines
|
EP2497831B1
(en)
|
2004-05-25 |
2014-07-16 |
Oregon Health and Science University |
TB vaccination using HCMV-based vaccine vectors
|
EP1768662A2
(en)
|
2004-06-24 |
2007-04-04 |
Novartis Vaccines and Diagnostics, Inc. |
Small molecule immunopotentiators and assays for their detection
|
EP1765313A2
(en)
|
2004-06-24 |
2007-03-28 |
Novartis Vaccines and Diagnostics, Inc. |
Compounds for immunopotentiation
|
EP2612679A1
(en)
|
2004-07-29 |
2013-07-10 |
Novartis Vaccines and Diagnostics, Inc. |
Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
EP2682126B1
(en)
|
2005-01-27 |
2016-11-23 |
Children's Hospital & Research Center at Oakland |
GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
MX291624B
(es)
|
2005-02-18 |
2011-11-04 |
Novartis Vaccines & Diagnostic |
Inmunogenos de escherichia coli uropatogenica.
|
AU2006214064B2
(en)
|
2005-02-18 |
2012-04-26 |
J. Craig Venter Institute, Inc. |
Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
|
JP2008534594A
(ja)
|
2005-03-31 |
2008-08-28 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
クラミジア感染に対するワクチン
|
ZA200800146B
(en)
*
|
2005-08-03 |
2009-10-28 |
Immunogen Inc |
Immunoconjugate formulations
|
WO2007047749A1
(en)
|
2005-10-18 |
2007-04-26 |
Novartis Vaccines And Diagnostics Inc. |
Mucosal and systemic immunizations with alphavirus replicon particles
|
EP1776963A1
(en)
|
2005-10-19 |
2007-04-25 |
Gbf-Gesellschaft Für Biotechnologische Forschung Mbh |
Hexosylceramides as adjuvants and their uses in pharmaceutical compositions
|
PT2368572T
(pt)
|
2005-11-04 |
2020-06-16 |
Seqirus Uk Ltd |
Vacinas com adjuvante dotadas de antigénios não-virião preparados a partir de vírus da gripe cultivado em cultura celular
|
CA2630220C
(en)
|
2005-11-22 |
2020-10-13 |
Doris Coit |
Norovirus and sapovirus antigens
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
KR20080089663A
(ko)
|
2006-01-27 |
2008-10-07 |
노바티스 백신즈 앤드 다이아그노스틱스 게엠베하 운트 콤파니 카게 |
적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신
|
ATE539079T1
(de)
|
2006-03-23 |
2012-01-15 |
Novartis Ag |
Imidazochinoxalinverbindungen als immunmodulatoren
|
AU2007231027B2
(en)
|
2006-03-24 |
2013-10-03 |
Novartis Influenza Vaccines Marburg Gmbh |
Storage of influenza vaccines without refrigeration
|
SG173336A1
(en)
|
2006-03-31 |
2011-08-29 |
Novartis Ag |
Combined mucosal and parenteral immunization against hiv
|
PT2054431E
(pt)
|
2006-06-09 |
2011-11-03 |
Novartis Ag |
Confórmeros de adesinas bacterianas
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
JP2010500399A
(ja)
|
2006-08-16 |
2010-01-07 |
ノバルティス アーゲー |
尿路病原性大腸菌由来の免疫原
|
EP1897557A1
(en)
*
|
2006-09-07 |
2008-03-12 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
Use of glycolipids as adjuvants
|
AU2007297178B2
(en)
|
2006-09-11 |
2014-07-24 |
Novartis Ag |
Making influenza virus vaccines without using eggs
|
WO2008068631A2
(en)
|
2006-12-06 |
2008-06-12 |
Novartis Ag |
Vaccines including antigen from four strains of influenza virus
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
DK2136836T3
(en)
|
2007-04-04 |
2017-04-10 |
Infectious Disease Res Inst |
Immunogenic compositions with mycobacterium tuberculosis polypeptides and fusions thereof
|
NZ582595A
(en)
|
2007-06-27 |
2012-07-27 |
Novartis Ag |
Low-additive influenza vaccines
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
BRPI0815008B8
(pt)
|
2007-08-02 |
2021-05-25 |
Biondvax Pharmaceuticals Ltd |
vacinas multiméricas com múltiplos epítopos contra influenza
|
JP2010535504A
(ja)
|
2007-08-03 |
2010-11-25 |
プレジデント アンド フェロウズ オブ ハーバード カレッジ |
クラミジア抗原
|
MX2010002773A
(es)
|
2007-09-12 |
2010-03-31 |
Novartis Ag |
Antigenos mutantes de gas57 y anticuerpos de gas57.
|
EP2570137A3
(en)
|
2007-11-07 |
2013-08-21 |
Celldex Therapeutics, Inc. |
Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
CA2744739A1
(en)
|
2007-12-03 |
2009-06-11 |
President And Fellows Of Harvard College |
Chlamydia antigens
|
US8815253B2
(en)
|
2007-12-07 |
2014-08-26 |
Novartis Ag |
Compositions for inducing immune responses
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
JP5656642B2
(ja)
|
2007-12-21 |
2015-01-21 |
ノバルティス アーゲー |
ストレプトリシンoの変異体形態
|
CA2716212A1
(en)
|
2008-02-21 |
2009-08-27 |
Novartis Ag |
Meningococcal fhbp polypeptides
|
US9511131B2
(en)
|
2008-03-10 |
2016-12-06 |
Children's Hospital & Research Center Oakland |
Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
|
KR20110091560A
(ko)
|
2008-12-03 |
2011-08-11 |
프로테아 벡신 테크놀로지스 엘티디. |
글루타밀 tRNA 합성효소(GtS) 단편들
|
KR101644221B1
(ko)
|
2008-12-09 |
2016-07-29 |
화이자 백신스 엘엘씨 |
IgE CH3 펩티드 백신
|
CN102481349B
(zh)
|
2009-01-12 |
2014-10-15 |
诺华股份有限公司 |
抗革兰氏阳性细菌疫苗中的Cna_B结构域
|
EP2403526B1
(en)
|
2009-03-06 |
2019-05-15 |
GlaxoSmithKline Biologicals SA |
Chlamydia antigens
|
JP5830009B2
(ja)
|
2009-04-14 |
2015-12-09 |
ノバルティス アーゲー |
Staphylococcusaureusに対して免疫化するための組成物
|
RU2536248C2
(ru)
|
2009-04-30 |
2014-12-20 |
Коули Фармасьютикал Груп, Инк. |
Пневмококковая вакцина и ее применения
|
DK2442826T3
(en)
|
2009-06-15 |
2015-09-21 |
Univ Singapore |
Influenza vaccine, composition and methods of using
|
SG177533A1
(en)
|
2009-07-07 |
2012-02-28 |
Novartis Ag |
Conserved escherichia coli immunogens
|
US20120164176A1
(en)
|
2009-07-15 |
2012-06-28 |
Kurt Swanson |
Rsv f protein compositions amd methods for making same
|
SG178035A1
(en)
|
2009-07-16 |
2012-03-29 |
Novartis Ag |
Detoxified escherichia coli immunogens
|
NZ598356A
(en)
|
2009-07-30 |
2014-06-27 |
Pfizer Vaccines Llc |
Antigenic tau peptides and uses thereof
|
JP2013502918A
(ja)
|
2009-08-27 |
2013-01-31 |
ノバルティス アーゲー |
髄膜炎菌fHBP配列を含むハイブリッドポリペプチド
|
MX2012002639A
(es)
|
2009-09-03 |
2012-03-14 |
Pfizer Vaccines Llc |
Vacuna de pcsk9.
|
US8974799B2
(en)
|
2009-09-30 |
2015-03-10 |
Novartis Ag |
Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
EP2493499A1
(en)
|
2009-10-27 |
2012-09-05 |
Novartis AG |
Modified meningococcal fhbp polypeptides
|
CN102753582A
(zh)
|
2009-11-03 |
2012-10-24 |
莱戈赛特医药股份有限公司 |
嵌合RSV-F多肽、和慢病毒或α-反转录病毒GAG基VLP
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
WO2011067758A2
(en)
|
2009-12-02 |
2011-06-09 |
Protea Vaccine Technologies Ltd. |
Immunogenic fragments and multimers from streptococcus pneumoniae proteins
|
CN107412754A
(zh)
|
2009-12-22 |
2017-12-01 |
塞尔德克斯医疗公司 |
疫苗组合物
|
US9173954B2
(en)
|
2009-12-30 |
2015-11-03 |
Glaxosmithkline Biologicals Sa |
Polysaccharide immunogens conjugated to E. coli carrier proteins
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
EP3327028B1
(en)
|
2010-03-30 |
2022-03-16 |
Children's Hospital & Research Center at Oakland |
Factor h binding proteins (fhbp) with altered properties and methods of use thereof
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
JP2013529894A
(ja)
|
2010-04-07 |
2013-07-25 |
ノバルティス アーゲー |
パルボウイルスb19のウイルス様粒子を生成するための方法
|
WO2011130434A2
(en)
|
2010-04-13 |
2011-10-20 |
Celldex Therapeutics Inc. |
Antibodies that bind human cd27 and uses thereof
|
EP2558069A1
(en)
|
2010-04-13 |
2013-02-20 |
Novartis AG |
Benzonapthyridine compositions and uses thereof
|
WO2011149564A1
(en)
|
2010-05-28 |
2011-12-01 |
Tetris Online, Inc. |
Interactive hybrid asynchronous computer game infrastructure
|
EP2942061A3
(en)
|
2010-06-07 |
2016-01-13 |
Pfizer Vaccines LLC |
Ige ch3 peptide vaccine
|
EP2576613A1
(en)
|
2010-06-07 |
2013-04-10 |
Pfizer Inc. |
Her-2 peptides and vaccines
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
CA2804501C
(en)
|
2010-07-06 |
2021-01-26 |
Novartis Ag |
Noro virus derived immunogenic compositions and methods
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
US20130345079A1
(en)
|
2010-10-27 |
2013-12-26 |
Infectious Disease Research Institute |
Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
|
ES2859673T3
(es)
|
2010-11-08 |
2021-10-04 |
Infectious Disease Res Inst |
Vacunas que comprenden polipéptidos de nucleósido hidrolasa no específica y esterol 24-c-metiltransferasa (SMT) para el tratamiento y el diagnóstico de la leishmaniasis
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
PT3023106T
(pt)
*
|
2010-12-14 |
2019-11-04 |
Glaxosmithkline Biologicals Sa |
Composição antigénica de micobactéria
|
WO2012085668A2
(en)
|
2010-12-24 |
2012-06-28 |
Novartis Ag |
Compounds
|
ES2727836T3
(es)
|
2011-01-26 |
2019-10-21 |
Glaxosmithkline Biologicals Sa |
Régimen de inmunización del VRS
|
AU2011360572B2
(en)
|
2011-02-22 |
2017-03-02 |
Biondvax Pharmaceuticals Ltd. |
Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
|
EP2680883B1
(en)
|
2011-03-02 |
2018-09-05 |
Pfizer Inc |
Pcsk9 vaccine
|
GB201106357D0
(en)
|
2011-04-14 |
2011-06-01 |
Pessi Antonello |
Composition and uses thereof
|
CA2835644C
(en)
|
2011-05-13 |
2021-06-15 |
Novartis Ag |
Pre-fusion rsv f antigens
|
JP2014527398A
(ja)
|
2011-06-21 |
2014-10-16 |
オンコファクター コーポレイション |
がんの療法および診断のための組成物および方法
|
CA2841047A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic compositions and uses thereof
|
CA2840989A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic combination compositions and uses thereof
|
EP2736921B1
(en)
|
2011-07-25 |
2018-06-27 |
GlaxoSmithKline Biologicals SA |
Compositions and methods for assessing functional immunogenicity of parvovirus vaccines
|
GB201114923D0
(en)
|
2011-08-30 |
2011-10-12 |
Novartis Ag |
Immunogenic proteins and compositions
|
JP2014531442A
(ja)
|
2011-09-14 |
2014-11-27 |
ノバルティス アーゲー |
Escherichiacoliワクチンの組み合わせ
|
WO2013084071A2
(en)
|
2011-12-08 |
2013-06-13 |
Novartis Ag |
Clostridium difficile toxin-based vaccine
|
WO2013108272A2
(en)
|
2012-01-20 |
2013-07-25 |
International Centre For Genetic Engineering And Biotechnology |
Blood stage malaria vaccine
|
WO2013124473A1
(en)
|
2012-02-24 |
2013-08-29 |
Novartis Ag |
Pilus proteins and compositions
|
EP2833900B1
(en)
|
2012-04-01 |
2018-09-19 |
Technion Research & Development Foundation Limited |
Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
|
EP3804749A3
(en)
|
2012-04-26 |
2021-07-28 |
GlaxoSmithKline Biologicals S.A. |
Antigens and antigen combinations
|
US10279026B2
(en)
|
2012-04-26 |
2019-05-07 |
Glaxosmithkline Biologicals Sa |
Antigens and antigen combinations
|
EP2659906A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP2659907A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP2659908A1
(en)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
RU2737765C2
(ru)
|
2012-05-04 |
2020-12-02 |
Пфайзер Инк. |
Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
|
US10124051B2
(en)
|
2012-05-22 |
2018-11-13 |
Glaxosmithkline Biologicals Sa |
Meningococcus serogroup X conjugate
|
CN104853770A
(zh)
|
2012-07-06 |
2015-08-19 |
诺华股份有限公司 |
免疫原性组合物及其应用
|
RU2659149C2
(ru)
|
2012-08-03 |
2018-06-28 |
Инфекшес Дизиз Рисерч Инститьют |
Композиции и способы для лечения активной инфекции mycobacterium tuberculosis
|
CA2885625A1
(en)
|
2012-10-02 |
2014-04-10 |
Glaxosmithkline Biologicals S.A. |
Nonlinear saccharide conjugates
|
AR092897A1
(es)
|
2012-10-03 |
2015-05-06 |
Novartis Ag |
Composiciones inmunogenicas
|
SI2925355T1
(en)
|
2012-11-30 |
2018-04-30 |
Glaxosmithkline Biologicals S.A. |
Antigens and combinations of Pseudomonas antigens
|
ES2728865T3
(es)
|
2013-03-28 |
2019-10-29 |
Infectious Disease Res Inst |
Vacunas que comprenden polipéptidos de Leishmania para el tratamiento y el diagnóstico de la leishmaniasis
|
CN112999344A
(zh)
|
2013-05-15 |
2021-06-22 |
阿尔伯达大学董事会 |
E1e2 hcv疫苗及使用方法
|
AU2015208821B2
(en)
|
2014-01-21 |
2017-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2015123291A1
(en)
|
2014-02-11 |
2015-08-20 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Pcsk9 vaccine and methods of using the same
|
WO2016014719A1
(en)
|
2014-07-23 |
2016-01-28 |
Children's Hospital & Research Center Oakland |
Factor h binding protein variants and methods of use thereof
|
AU2015252119A1
(en)
|
2014-11-07 |
2016-05-26 |
Takeda Vaccines, Inc. |
Hand, foot, and mouth vaccines and methods of manufacture and use thereof
|
MA40920A
(fr)
|
2014-11-07 |
2017-09-12 |
Takeda Vaccines Inc |
Vaccins de la main, du pied et de la bouche, et procédés de fabrication et d'utilisation de ceux-ci
|
JP6738348B2
(ja)
|
2014-12-19 |
2020-08-12 |
リジェネサンス ベスローテン フェンノートシャップ |
ヒトc6に結合する抗体およびその使用
|
PL3244917T3
(pl)
|
2015-01-15 |
2023-07-17 |
Pfizer Inc. |
Kompozycje immunogenne do zastosowania w szczepionkach przeciwko pneumokokom
|
EP3268037B1
(en)
|
2015-03-09 |
2022-08-31 |
Celldex Therapeutics, Inc. |
Cd27 agonists
|
CA2986961C
(en)
|
2015-05-26 |
2023-07-25 |
Ohio State Innovation Foundation |
Nanoparticle based vaccine strategy against swine influenza virus
|
JP2018521016A
(ja)
|
2015-06-03 |
2018-08-02 |
アフィリス・アクチェンゲゼルシャフトAffiris Ag |
IL−23−p19ワクチン
|
WO2017005851A1
(en)
|
2015-07-07 |
2017-01-12 |
Affiris Ag |
Vaccines for the treatment and prevention of ige mediated diseases
|
KR102225282B1
(ko)
|
2015-07-21 |
2021-03-10 |
화이자 인코포레이티드 |
접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
|
WO2017085586A1
(en)
|
2015-11-20 |
2017-05-26 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
TWI709647B
(zh)
|
2016-01-19 |
2020-11-11 |
美商輝瑞股份有限公司 |
癌症疫苗
|
CN109071665B
(zh)
|
2016-04-18 |
2022-11-01 |
塞德斯医疗公司 |
结合人cd40的激动性抗体及其用途
|
WO2017205225A2
(en)
|
2016-05-21 |
2017-11-30 |
Infectious Disease Research Institute |
Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections
|
MX2019003035A
(es)
|
2016-09-16 |
2019-09-13 |
Infectious Disease Res Inst |
Vacunas que comprenden polipeptidos de mycobacterium leprae para la prevencion, el tratamiento y el diagnostico de la lepra.
|
HRP20220573T1
(hr)
|
2017-01-20 |
2022-06-10 |
Pfizer Inc. |
Imunogeni pripravci, namijenjeni upotrebi u pneumokoknim cjepivima
|
WO2019035963A1
(en)
|
2017-08-16 |
2019-02-21 |
Ohio State Innovation Foundation |
NANOPARTICLE COMPOSITIONS FOR VACCINES AGAINST SALMONELLA
|
MY193736A
(en)
|
2017-11-03 |
2022-10-27 |
Takeda Vaccines Inc |
Method for inactivating zika virus and for determining the completeness of inactivation
|
US11633471B2
(en)
|
2018-03-06 |
2023-04-25 |
Unm Rainforest Innovations |
Compositions and methods for reducing serum triglycerides
|
US20210198374A1
(en)
|
2018-04-17 |
2021-07-01 |
Celldex Therapeutics, Inc. |
Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
CN111315407B
(zh)
|
2018-09-11 |
2023-05-02 |
上海市公共卫生临床中心 |
一种广谱抗流感疫苗免疫原及其应用
|
WO2020123444A1
(en)
|
2018-12-11 |
2020-06-18 |
Celldex Therapeutics, Inc. |
Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
|
EP3893926A1
(en)
|
2018-12-12 |
2021-10-20 |
Pfizer Inc. |
Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
US20220184199A1
(en)
|
2019-04-10 |
2022-06-16 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
MX2022005252A
(es)
|
2019-11-01 |
2022-06-08 |
Pfizer |
Composiciones de escherichia coli y metodos de las mismas.
|
NL2030835B1
(en)
|
2020-01-24 |
2022-12-29 |
Aim Immunotech Inc |
Methods, compositions, and vaccinces for treating a virus infection
|
CN115362177A
(zh)
|
2020-02-21 |
2022-11-18 |
辉瑞公司 |
糖类的纯化
|
MX2022010350A
(es)
|
2020-02-23 |
2022-09-19 |
Pfizer |
Composiciones de esquerichia coli y sus metodos.
|
EP4114848A4
(en)
|
2020-02-26 |
2024-04-03 |
Versitech Limited |
PD-1-BASED VACCINES AGAINST CORONAVIRUS INFECTION
|
JP2023535730A
(ja)
*
|
2020-07-24 |
2023-08-21 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
Covid-19の3成分ワクチン
|
JP2023546615A
(ja)
|
2020-10-27 |
2023-11-06 |
ファイザー・インク |
大腸菌組成物およびその方法
|
AU2021373358A1
(en)
|
2020-11-04 |
2023-06-01 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
CA3200968A1
(en)
|
2020-11-10 |
2022-05-19 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
US20220202923A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
E. coli fimh mutants and uses thereof
|
WO2022147373A1
(en)
|
2020-12-31 |
2022-07-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
|
TW202245836A
(zh)
|
2021-02-19 |
2022-12-01 |
美商賽諾菲巴斯德公司 |
重組b型腦膜炎球菌疫苗
|
AU2022253269A1
(en)
|
2021-04-09 |
2023-11-23 |
Celldex Therapeutics, Inc. |
Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
|
WO2022234483A1
(en)
|
2021-05-04 |
2022-11-10 |
King Abdullah University Of Science And Technology |
Immuogenic compositions of mutant sars-cov-2 n protein and gene and methods of use thereof
|
WO2022249106A2
(en)
|
2021-05-28 |
2022-12-01 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
US20220387576A1
(en)
|
2021-05-28 |
2022-12-08 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2023079529A1
(en)
|
2021-11-05 |
2023-05-11 |
King Abdullah University Of Science And Technology |
Re-focusing protein booster immunization compositions and methods of use thereof
|
WO2023079528A1
(en)
|
2021-11-05 |
2023-05-11 |
King Abdullah University Of Science And Technology |
Compositions suitable for use in a method for eliciting cross-protective immunity against coronaviruses
|
WO2023077521A1
(en)
|
2021-11-08 |
2023-05-11 |
Celldex Therapeutics, Inc |
Anti-ilt4 and anti-pd-1 bispecific constructs
|
AU2022391752A1
(en)
|
2021-11-18 |
2024-06-13 |
Matrivax, Inc. |
Immunogenic fusion protein compositions and methods of use thereof
|
WO2023135515A1
(en)
|
2022-01-13 |
2023-07-20 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
KR102420201B1
(ko)
*
|
2022-01-17 |
2022-07-13 |
주식회사 유이케미칼 |
인지질 외피 보유 바이러스 사멸기능을 가지는 친환경 방역 조성물
|
WO2023161817A1
(en)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Methods for incorporating azido groups in bacterial capsular polysaccharides
|
WO2023218322A1
(en)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Process for producing of vaccine formulations with preservatives
|
WO2024018061A1
(en)
|
2022-07-22 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Use of bordetella strains for the treatment of chronic obstructive pulmonary disease
|
WO2024110827A1
(en)
|
2022-11-21 |
2024-05-30 |
Pfizer Inc. |
Methods for preparing conjugated capsular saccharide antigens and uses thereof
|
US20240181028A1
(en)
|
2022-11-22 |
2024-06-06 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2024116096A1
(en)
|
2022-12-01 |
2024-06-06 |
Pfizer Inc. |
Pneumococcal conjugate vaccine formulations
|
WO2024130009A1
(en)
|
2022-12-14 |
2024-06-20 |
Yale University |
Compositions and methods of use thereof for the treatment of virally driven cancers
|